Chinese Heavy Ion Technology Goes to the United States — China Heavy Ion, Health for the World
Chinese Heavy Ion Technology Goes to the United States
— China Heavy Ion, Health for the World
On October 1st, Chinese heavy ion technology made a remarkable appearance at the 67th Annual Meeting of the American Society for Radiation Oncology (ASTRO) in San Francisco, USA. At this premier event gathering over 10,000 radiation oncology professionals worldwide, the Wuwei Heavy Ion Center systematically presented its full-chain technological achievements. With an attitude of "confidence in technology, confidence in products, and confidence in management," it made Chinese heavy ion technology a focus of this year's annual meeting, further conveying the firm commitment of "Intelligent Manufacturing from China" to serving global health.
As a global "weather vane" in radiation oncology established in 1958, the ASTRO annual meeting has always been an arena for cutting-edge international technologies. The debut of Chinese heavy ion technology this time was not merely a simple display of achievements, but a declaration of strength, transitioning from "catching up" to "leading the way." Behind this lies the Wuwei Heavy Ion Center's inheritance of the "Wuwei Spirit" – "Not bowing to difficulties, daring to turn the desert into an oasis" – and a legendary story of overcoming adversity written through more than a decade of breaking barriers and tackling hard challenges. Looking back to 2012, heavy ion cancer therapy technology was still confined to laboratories, not yet truly applied clinically. The research team at the Wuwei Heavy Ion Center endured numerous hardships, conducting day-and-night research and repeated trial assemblies, ultimately propelling Chinese heavy ion technology from the research stage to the clinical frontline, making it a benchmark for independent innovation in China's high-end medical equipment.
At the exhibition, the Wuwei Heavy Ion Center showcased a "hardcore report card" featuring "eight world's and domestic firsts," providing evidence of its leading position in heavy ion technology: It is the only hospital globally operating two heavy ion treatment systems. With the Lanzhou Heavy Ion Center, also under its operation, coming online half a year ago, a powerful pattern of dual-center synergy has been formed, significantly enhancing the treatment capacity and reach of heavy ion therapy. In treatment techniques, the center continuously explores boundaries, performing the highest number globally of single-fraction treatments completed within one day, greatly shortening treatment cycles and reducing suffering for patients. It pioneered globally the techniques of precise heavy ion therapy under respiratory gating, bladder cancer treatment under precise bladder volume control, and single-session heavy ion therapy following surgical placement of a spacer between organs and tumors. Each breakthrough embodies the wisdom and dedication of the research and clinical teams, bringing new hope to countless patients with complex conditions. Domestically, it first developed a 360-degree rotatable and adjustable ion therapy chair, providing strong support for precise treatment. Globally, it was the first to complete heavy ion treatment for multiple cases of cardiac tumors and the first to implement heavy ion therapy combined with comprehensive, whole-life-cycle physical and mental health management. From treatment techniques to service philosophy, it leads the development trend of heavy ion therapy in all aspects.
Behind this report card lies the deep integration of technological breakthroughs and clinical practice. The center's clinical capabilities have achieved a qualitative leap: the range of treatable diseases has expanded from 7 types during the 2018 clinical trial period to over 50 types, with standardized diagnosis and treatment protocols tailored to the characteristics of Chinese patients established for each. The annual number of treatments has surged from 200 to nearly 1,000, with an average annual growth rate of 17.5%. Both treatment efficiency and efficacy have reached internationally advanced levels. To date, the center has brought hope to over 2,300 patients, with its services covering all provinces and municipalities in China (including Taiwan, Hong Kong, and Macao), as well as countries such as Australia, Belgium, South Korea, Vietnam, Thailand, and Malaysia. The international recognition and standard-setting influence of Chinese heavy ion technology continue to rise, allowing the "Chinese Solution" to emerge prominently in the global field of cancer treatment.
To continuously consolidate its technological advantages and improve the standard system, Gansu Wuwei Cancer Hospital has long been building an international platform for expert collaboration. While introducing global top-tier medical expertise, it actively exports Chinese standards: It has successively appointed internationally authoritative experts such as Professor Tatsuaki Kanai from the University of Gunma Faculty of Medicine, Japan; Professor Hirohiko Tsujii, former President of the National Institute of Radiological Sciences (NIRS), Japan; Professor Jörg Hauffe, former Director of the RPTC Munich Proton Therapy Center, Germany; Professor Olga; Professor Yi-Min Jen, former Chairman of the Taiwanese Society of Therapeutic Radiation Oncology, and others. Through technical exchanges, it promotes the alignment of Chinese standards with international norms. Recently, it further introduced Professor Yasuo Yoshioka from the Department of Radiation Oncology at the Japanese Foundation for Cancer Research and Professor György Kovács, Director of the Center for Brachytherapy Lübeck, Germany (also Director of Educational Programs at the Università Cattolica del Sacro Cuore, Italy), for long-term residency. By integrating Chinese diagnostic and treatment standards into clinical training and technical guidance, it lays a solid foundation for building a tumor treatment system with international competitiveness and a platform for standard export.
This appearance at the ASTRO annual meeting is a key step for the Wuwei Heavy Ion Center in promoting the internationalization of its technology. Within the framework of ASTRO's philosophy of "Improving the Quality of Patient Care Globally," the center not only brought a full-chain solution from equipment development to clinical application but also built bridges for international cooperation with an open attitude – transitioning from a "game-changer" breaking monopolies to a "contributor" in the global market. Chinese heavy ion technology is gradually gaining international discourse power in the field of radiation oncology by virtue of its hard power in independent innovation.
Breaking technological monopolies is just the starting point; enabling global patients to share the benefits of Chinese technology is the ultimate goal. Next, the Wuwei Heavy Ion Center will use this annual meeting as an opportunity to accelerate the global deployment of domestically produced heavy ion equipment and promote "Intelligent Manufacturing from Gansu" into hospitals worldwide. In the future, this technological achievement, born in the Northwest and inheriting the spirit of "turning the desert into an oasis," will not only contribute the "Chinese Solution" to global cancer treatment but also become a beautiful medical name card for the country's foreign relations. Under the mission of "China Heavy Ion, Health for the World," it will inject strong Chinese strength into the global health cause.
